Revolution Medicines (RVMD) Accumulated Depreciation & Amortization (2018 - 2025)
Historic Accumulated Depreciation & Amortization for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $27.0 million.
- Revolution Medicines' Accumulated Depreciation & Amortization rose 2464.36% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 2464.36%. This contributed to the annual value of $21.8 million for FY2024, which is 33646.0% up from last year.
- As of Q3 2025, Revolution Medicines' Accumulated Depreciation & Amortization stood at $27.0 million, which was up 2464.36% from $25.0 million recorded in Q2 2025.
- Revolution Medicines' Accumulated Depreciation & Amortization's 5-year high stood at $27.0 million during Q3 2025, with a 5-year trough of $700000.0 in Q1 2021.
- Its 5-year average for Accumulated Depreciation & Amortization is $11.9 million, with a median of $15.7 million in 2023.
- As far as peak fluctuations go, Revolution Medicines' Accumulated Depreciation & Amortization skyrocketed by 1250.0% in 2022, and later surged by 176988.89% in 2023.
- Revolution Medicines' Accumulated Depreciation & Amortization (Quarter) stood at $3.1 million in 2021, then rose by 29.03% to $4.0 million in 2022, then increased by 25.0% to $5.0 million in 2023, then skyrocketed by 336.46% to $21.8 million in 2024, then increased by 23.79% to $27.0 million in 2025.
- Its Accumulated Depreciation & Amortization was $27.0 million in Q3 2025, compared to $25.0 million in Q2 2025 and $23.4 million in Q1 2025.